Unconfigured Ad

Collapse
X
 
  • Time
  • Show
Clear All
new posts
  • hollystephens723
    Member
    • Dec 2018
    • 36

    #1

    PrecisionFDA FDA Open Data Challenge Update

    For those interested in participating in the precisionFDA Gaining New Insights by Detecting Adverse Event Anomalies Using FDA Open Data Challenge, you have 10-days days left to complete your submission. Selected participants will be invited to participate in a panel at the Modernizing FDA’s Data Strategy public meeting. Final submissions are due on February 28th, and providing code is no longer required for a valid entry. Additionally, new guidance is available on the challenge site including updated evaluation criteria and anomaly examples.


    If you are interested in learning more about how FDA is modernizing its data strategy, please attend the Modernizing FDA’s Data Strategy public meeting on March 27th. The meeting will also be streamed virtually for those who don’t live in the DC area!

    If you have any questions about the challenge, please feel free to post them in this thread and we will respond as quickly as possible.
  • hollystephens723
    Member
    • Dec 2018
    • 36

    #2
    We are pleased to announce that the Journal of the American Medical Informatics Association (JAMIA) supports the submission of a paper describing the precisionFDA Gaining New Insights by Detecting Adverse Event Anomalies Using FDA Open Data challenge and broadly applicable insights that emerge from it. Publication in JAMIA will be contingent on a standard evaluation process including editorial assessment and peer review.

    As a friendly reminder for those of you participating in the challenge you have one week left before final submissions are due on February 28th at https://go.usa.gov/xdEW2.

    If you have any questions about the challenge, please feel free to post them in this thread and we will respond as quickly as possible.

    Comment

    Latest Articles

    Collapse

    • SEQadmin2
      Multiomic Liquid Biopsy: What DNA/RNA Panels Reveal That DNA Alone Can’t
      by SEQadmin2



      Tumors contain complex mixtures of cell populations that evolve in response to treatment and host-specific factors. Tissue biopsies provide only static snapshots of a tumor’s state. But what if we could follow that evolution over time using a minimally invasive technique?

      Liquid biopsies can detect tumor-derived material circulating in the bloodstream, providing a way to study treatment response, detect emerging resistance, and discover new biomarkers. Circulating
      ...
      10-14-2026, 09:55 AM
    • SEQadmin2
      New Genomics Technologies Take Aim at Long-Standing Limits
      by SEQadmin2


      Researchers using sequencing and genomics tools often have to make trade-offs. They can choose between speed or scale, short reads or long-range information, or targeted panels or a view of the whole transcriptome. New technologies that have been released this year are built to address those tough choices.

      We asked six companies the same four questions to learn about their latest products. The new technologies bring a lot to the table, including rethinking sequencing
      ...
      09-28-2026, 10:25 AM

    ad_right_rmr

    Collapse

    News

    Collapse

    Topics Statistics Last Post
    Started by SEQadmin2, 10-22-2026, 11:13 AM
    0 responses
    26 views
    0 reactions
    Last Post SEQadmin2  
    Started by SEQadmin2, 10-22-2026, 10:48 AM
    0 responses
    20 views
    0 reactions
    Last Post SEQadmin2  
    Started by SEQadmin2, 10-15-2026, 10:52 AM
    0 responses
    36 views
    0 reactions
    Last Post SEQadmin2  
    Started by SEQadmin2, 10-14-2026, 05:39 AM
    0 responses
    43 views
    0 reactions
    Last Post SEQadmin2  
    Working...